Coeptis Therapeutics Holdings, Inc. (COEP)
NASDAQ: COEP · Real-Time Price · USD
0.194
-0.001 (-0.51%)
At close: Nov 20, 2024, 4:00 PM
0.200
+0.006 (3.25%)
Pre-market: Nov 21, 2024, 7:00 AM EST
COEP Employees
As of December 31, 2023, Coeptis Therapeutics Holdings had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees increased by 2 or 40.00% compared to the previous year.
Employees
7
Change (1Y)
2
Growth (1Y)
40.00%
Revenue / Employee
n/a
Profits / Employee
-$1,672,975
Market Cap
7.69M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7 | 2 | 40.00% |
Dec 31, 2022 | 5 | 0 | - |
Dec 31, 2021 | 5 | 0 | - |
Dec 31, 2020 | 5 | - | - |
Related Stocks
Company Name | Employees |
---|---|
XWELL | 337 |
Ontrak | 104 |
Mustang Bio | 80 |
Syros Pharmaceuticals | 68 |
NeuroMetrix | 26 |
Moleculin Biotech | 18 |
Galecto | 13 |
Cardio Diagnostics Holdings | 9 |
COEP News
- 14 days ago - Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development - PRNewsWire
- 4 weeks ago - Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use - PRNewsWire
- 5 weeks ago - Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy - PRNewsWire
- 2 months ago - Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing - PRNewsWire
- 2 months ago - Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders - PRNewsWire
- 5 months ago - Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering - PRNewsWire
- 6 months ago - Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting - PRNewsWire
- 7 months ago - Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 - PRNewsWire